ClinicalTrials.gg
RecruitingNCT06353542BEGASUpdated Oct 9, 2024

Barcelona Esquerra Glaucoma Artificial Intelligence-based Screening Program (BEGAS)

An interventional study of Software analysis and Ophthalmologist examination in Glaucoma, sponsored by Hospital Clinic of Barcelona. Recruiting at 1 site in Spain. Open to participants aged 40 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-09.

Sponsored by Hospital Clinic of Barcelona · Not applicable, Interventional, and Screening

How we know

From the registry’s dates

  • Primary completion was expected by Mar 2026, 8 months ago, but the record still lists the study as recruiting.
  • Started May 2024; still recruiting 2 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
500
Allocation
Randomized
Ages
40 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 43 studies in Glaucoma with a site in Spain — 7 open to participants now, 7 under way, none of them phase 3. Glaucoma · Spain.

Planned enrollment
4th of 33
500 · median 100
Started
2024
with 1 other
No phase
16 of 43
3 open now
Registered
39th of 43
by date
Lead sponsor
2 of 43
Hospital Clinic of Barcelona

Among the 43 studies in Glaucoma with a site in Spain, this one is the 4th largest by planned enrollment of the 33 interventional ones that give a count, is one of 2 that started in 2024, is one of 16 with no phase, and was the 39th registered.

Glaucoma

1,421 studies on the registry are indexed under Glaucoma; 221 are open to participants now.

Browse Glaucoma studies →

Open to participants now

7 of the 43 studies in Glaucoma with a site in Spain are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 154 Glaucoma studies recruiting now, 112 (73%) set no upper age limit and 9 (6%) stop at 75 or younger; 13 take children under 18; 44 take healthy volunteers.

This study: 40 Years to 80 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies in Glaucoma with a site in Spain, or all of them as a file.
02

Study summary

Two primary care-based screening systems will be tested to identify subjects with referrable glaucoma to hospital care.

Subjects between 45 to 64 years old living in the metropolitan area of Barcelona will be invited to participate in a one-time visit, with an optic disc examination and intraocular pressure (IOP).

The criteria for referring a patient will be the detection of glaucoma but with two different approaches depending on which Integrated Practice Unit (IPU) the patients will be allocated to: one arm using an Artificial Intelligence (AI) reading software of the optic disc picture; and the other one will base their referral after an ophthalmic examination performed by an ophthalmologist.

In both circuits, an optic nerve head photography will be obtained, and a masked reading center will be established to determine the ground truth for diagnosis.

This screening trial will explore the level of agreement between both systems and the cost-effectiveness of each of them.

Secondary analyses will include potential diagnostic composite scores (including other ancillary tests, such as optical coherence tomography images, that could maximize the screening process); the identification of population and disease characteristics (type of glaucoma, intraocular pressure) that could increase the effectivity and adherence to the screening process.

Read the detailed description

The purpose of this study is twofold: to validate in our population an Artificial Intelligence (AI) reading software of the optic disc picture, after comparing the estimated result (glaucoma/suspect/normal) to the ground truth; and to conduct a clinical trial where the level of agreement between both systems and the cost-effectiveness of each of them will be tested

In the first phase, a set of patients from our reference population will be selected. A standard-of-care ophthalmic examination with the usual ancillary tests to confirm or rule out the presence of glaucoma (including an optic disc retinography), will be performed. The patient (and the test) will be examined by a glaucoma specialist who will determine the status of the patient.

Then, the retinography will be analyzed by the AI software, providing the estimated result (glaucoma/suspect/normal). The level of agreement between the ground truth and the casted result will confirm the diagnostic accuracy.

In the second phase, a second set of patients will be recruited. In this case, the patients will be randomly allocated to either of the two arms of the study: In arm A the ancillary tests (including the retinography) will be performed, and the software will analyze the retinography, therefore providing the glaucoma status result. In arm B, the patients (and the test) will be examined by a glaucoma specialist who will then determine the status of the patient.

All the patients, irrespective of the diagnosis and the arm of the study will be then explored by another glaucoma specialist (reading center), who will be blinded to where the diagnosis comes from (AI software or glaucoma specialist), to the determine the level of agreement between the two screening systems

03

Conditions studied

  • Glaucoma

Browse trials for

Keywords

  • Artificial Intelligence
  • Diagnostic Test: Glaucoma Screening
04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged 40 to 80 years old from our reference population
  • Family history of glaucoma
  • Willingness to participate
  • Signed written

Exclusion criteria

Exclusion Criteria:

  • Not signing the
  • Patients that had a previous diagnosis of glaucoma or any ophthalmic disease that required a regular ophthalmic examination and/or treatment
  • Congenital or childhood glaucoma
  • History of strabismus or amblyopia
  • Known ophthalmic diseases which imply media opacity (cataract, cornea opacities) that might preclude from taking fundus retinographies
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Care provider, Investigator)
Enrollment
500 participants (estimated)

Study arms

  • Experimental
    AI software examination (A)

    In arm A, the visual acuity, refraction status and the ancillary tests will be performed. The obtained optic disc retinography will be analyzed by the AI software to determine whether the patient was a glaucomatous, suspect or healthy patient.

    Diagnostic Test: Software analysis

  • Active comparator
    Ophthalmic examination (B)

    In arm B, the visual acuity, refraction status and the ancillary tests will be performed, and then the patients (and the test) will be examined by a glaucoma specialist who will determine the status of the patient (glaucomatous, suspect or healthy).

    Diagnostic Test: Ophthalmologist examination

Interventions

  • Diagnostic testSoftware analysis

    The tested AI software analyzes the optic disc retinography to determine if the patient is healthy, a glaucoma suspect, or a glaucoma case

  • Diagnostic testOphthalmologist examination

    The ophthalmologist (a glaucoma specialist) will analyze the tests and will examine the patient to determine if the patient is healthy, a glaucoma suspect or a glaucoma case

06

What researchers measure

Primary outcomes

  1. Diagnostic agreement between the AI software and the ophthalmic examination

    Level of agreement between the casted result by the AI software and the ophthalmic examination. This will be determined by the reading person (study chair)

    Time frame: 18 months

  2. Health-Related Quality of Life (HRQoL)

    Health-Related Quality of Life (HRQoL) assessed by Euro Quality of Life -5 Dimensions (EQ-5D), for each arm of the clinical trial. It consists of a visual analog scale, ranging from 0 to 100 (0 being the worst imaginable health and 100 the best health the patient can imagine)

    Time frame: 18 months

  3. Demographics

    Quantitative analysis of age, gender, ethnicity, and family history of glaucoma differences between the two arms

    Time frame: 18 months

Secondary outcomes

  1. Intraocular pressure

    Intraocular pressure values of glaucoma, suspects, and healthy patients of each arm of the study (in mmHg)

    Time frame: 18 months

  2. Optical coherence tomography (OCT)

    OCT values of glaucoma, suspects, and healthy patients of each arm of the study (thickness reported in micrometers)

    Time frame: 18 months

  3. Visual field

    Visual field defects (mean deviation, in decibels) of glaucoma, suspects, and healthy patients of each arm of the study

    Time frame: 18 months

  4. Cost-effective analysis of both screening methods

    Cost-effective analysis will be conducted on each arm of the study comparing direct costs, and degree of visual impairment and comparing it to other screening programs (case-finding scenario) Mean costs and effects to estimate the Incremental Cost-Effectiveness Ratio (ICER, in euros, €) for artificial intelligence software screening versus ophthalmic examination will be compared

    Time frame: 18 months

  5. Risk score with parameters associated with positive screening of glaucoma

    Analysis of the demographics (present or absent), ocular characteristics (present or absent), OCT values (in micrometers), and visual field values (in decibels) that could be associated with an increased likeliness of glaucoma diagnosis The degree of contribution of each parameter will be analyzed in a multivariate logistic regression, and then a risk score will be created using a scale from 1 to 100 (with being 1 the lowest value and 100 being the highest) to show how each parameter contributes to a "positive glaucoma diagnosis"

    Time frame: 6 months

07

Study locations

1 of 1 sites recruiting
  • Hospital Clínic - ICOF
    Barcelona, 08028, Spain
    Recruiting
    • Nestor Ventura Abreu, MD, PhD · Contactneventura@clinic.cat · +34932275400
    • Marta Pazos, MD, PhD · Contact
08

References and documents

Publications

  • Hemelings R, Elen B, Barbosa-Breda J, Lemmens S, Meire M, Pourjavan S, Vandewalle E, Van de Veire S, Blaschko MB, De Boever P, Stalmans I. Accurate prediction of glaucoma from colour fundus images with a convolutional neural network that relies on active and transfer learning. Acta Ophthalmol. 2020 Feb;98(1):e94-e100. doi: 10.1111/aos.14193. Epub 2019 Jul 25. PubMed 31344328 ↗
  • US Preventive Services Task Force; Davidson KW, Barry MJ, Mangione CM, Cabana M, Caughey AB, Davis EM, Donahue KE, Doubeni CA, Krist AH, Kubik M, Li L, Ogedegbe G, Owens DK, Pbert L, Silverstein M, Stevermer J, Tseng CW, Wong JB. Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2021 May 18;325(19):1965-1977. doi: 10.1001/jama.2021.6238. Erratum In: JAMA. 2021 Aug 24;326(8):773. doi: 10.1001/jama.2021.12404. PubMed 34003218 ↗
  • Tan NYQ, Friedman DS, Stalmans I, Ahmed IIK, Sng CCA. Glaucoma screening: where are we and where do we need to go? Curr Opin Ophthalmol. 2020 Mar;31(2):91-100. doi: 10.1097/ICU.0000000000000649. PubMed 31904596 ↗

Individual participant data

Plan to share: No — Individual Participant Data that could identify any patient will not be shared with other researchers. Patients will only be de-identified if a major health risk is detected, or under legal requirement by the competing authorities.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2024 (actual). Primary completion is estimated for Mar 2026, 22 months after the start.

Of 230 non-industry interventional studies with no phase under Glaucoma, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 55. This study's planned 22 months is below that.

Counting every sponsor, half of 288 studies reached it within 30 months; a quarter within 12 and three quarters within 53.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 21, 2024
First posted
Apr 9, 2024
StartActual
May 2, 2024
Primary completionEst.
Mar 2026
CompletionEst.
Sep 2026
Last update
Oct 9, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 9, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06353542
Responsible party
Sponsor
First posted
Apr 9, 2024
Start date
May 2, 2024
Primary completion
Mar 2026 (estimated)
Completion
Sep 2026 (estimated)
Last update
Oct 9, 2024

Study contacts

Nestor Ventura Abreu, MD, PhD
Contact
neventura@clinic.cat
+34932275400 ext. 9336
Marta Pazos, MD, PhD
study chair · Glaucoma Consultant - Head of Ophthalmic Surgery Department

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion